Marker Therapeutics, Inc. (MRKR) income statement
MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/30
$0.85+0.02 (+1.98%)
Close on Nov 18, 2026Market cap $14.23MP/E –Yield –
Marker Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -302.1%
- Net margin
- -245.5%
- Return on equity, FY2025
- -68.8%
Financial strength
- Current ratio
- 6.03
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 468.2%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.17
- Dividend yield
- –
See a number that looks wrong?